WikiDer > Gosogliptin

Gosogliptin
KARVONSAROY: Gosogliptin
Klinik ma'lumotlar
Boshqa ismlar	PF-734200
Identifikatorlar
	IUPAC nomi (3,3-Difluoro-1-pirrolidinil) {(2S,4S) -4- [4- (2-pirimidinil) -1-piperazinil] -2-pirrolidinil} metanon;
CAS raqami	869490-23-3;
PubChem CID	11516136;
DrugBank	DB08382;
ChemSpider	9690926;
UNII	GI718UO477;
CompTox boshqaruv paneli (EPA)	DTXSID601007213 ;
Kimyoviy va fizik ma'lumotlar
Formula	C17H24F2N6O
Molyar massa	366.417 g · mol−1
3D model (JSmol)	Interaktiv rasm;
	Jilmayganlar c1cnc (nc1) N2CCN (CC2) [C @ H] 3C [C @ H] (NC3) C (= O) N4CCC (C4) (F) F;
	InChI InChI = 1S / C17H24F2N6O / c18-17 (19) 2-5-25 (12-17) 15 (26) 14-10-13 (11-22-14) 23-6-8-24 (9-7-) 23) 16-20-3-1-4-21-16 / h1,3-4,13-14,22H, 2,5-12H2 / t13-, 14- / m0 / s1; Kalit: QWEWGXUTRTXFRF-KBPBESRZSA-N;

Gosogliptin

Gosogliptin (KARVONSAROY; savdo nomi SatRx) davolash uchun dori II turdagi diabet. Bu sinfda dipeptidil peptidaz-4 (DPP-4) inhibitörleri (gliptinlar deb ham ataladi). Bu topildi^[1] va 1-bosqich orqali ishlab chiqilgan^[2]^[3]^[4] va 2-bosqich^[5]^[6]^[7]tomonidan Pfizer. Gosogliptin bilan kompleksda DPP-4 ning kristalli tuzilishi mavjud.^[8] Sichqoncha, it va odamda uning metabolizmi, chiqarilishi va farmakokinetikasi tasvirlangan.^[9] Tejamkor yo'nalish e'lon qilindi.^[10] Boshqa tadqiqotlar^[11] shu jumladan Rossiyada 3-bosqich tadqiqotlari o'tkazildi.^[12]^[13] U Rossiyada foydalanish uchun tasdiqlangan.^[14]

Adabiyotlar

^ Ammirati MJ, Andrews KM, Boyer DD, Brodeur AM, Danley DE, Doran SD, Hulin B, Liu S, McPherson RK, Orena SJ, Parker JC, Polivkova J, Qiu X, Soglia CB, Treadway JL, VanVolkenburg MA, Wilder DC , Piotrowski DW (2009 yil aprel). "(3,3-Difloro-pirrolidin-1-il) - [(2S, 4S) - (4- (4-pirimidin-2-yl-piperazin-1-yl) -pirrolidin-2-yl] -metanon: kuchli, selektiv, og'iz orqali faol dipeptidil peptidaza IV inhibitori ". Bioorganik va tibbiy kimyo xatlari. 19 (7): 1991–1995. doi:10.1016 / j.bmcl.2009.02.041. PMID 19275964.
^ Dai H, Gustavson SM, Preston GM, Eskra JD, Calle R, Hirshberg B (2008). "Sog'lom kattalar sub'ektlarida DPP-IV inhibisyonuna javoban GLP-1 darajasining chiziqli bo'lmagan o'sishi". Qandli diabet, semirish va metabolizm. 10 (6): 506–513. doi:10.1111 / j.1463-1326.2007.00742.x. PMID 18284437. S2CID 13417601.
^ Dai H, Jonson SL, Terra SG, Marbury TC, Smit VB, Alkorn H, Boyd RA, Vang R, Nguyen TT (iyul 2011). "Buyrak etishmovchiligida bo'lgan DPP-IV inhibitori PF-734200 farmakokinetikasi". Britaniya klinik farmakologiya jurnali. 72 (1): 85–91. doi:10.1111 / j.1365-2125.2011.03954.x. PMC 3141189. PMID 21366665.
^ Muto C, Dai H, Teeter JG, Jonson S, Cropp AB, Chiba K, Suwa T (2012). "Sog'lom yapon sub'ektlarida DPP-IV inhibitori PF-00734200 ning farmakokinetikasi va farmakodinamikasi". Xalqaro klinik farmakologiya va terapiya jurnali. 50 (7): 505–509. doi:10.5414 / CP201614. PMID 22541754.
^ Rosenstock J, Lewin AJ, Norwood P, Somayaji V, Nguyen TT, Teeter JG, Jonson SL, Dai H, Terra SG (2011). "2-toifa diabetda metforminga qo'shilgan dipeptidil peptidaza-4 inhibitori PF ‐ 734200 ning samaradorligi va xavfsizligi". Diabetik tibbiyot. 28 (4): 464–469. doi:10.1111 / j.1464-5491.2010.03181.x. PMID 21392067. S2CID 205550845.
^ https://clinicaltrials.gov/ct2/show/NCT00618007
^ https://clinicaltrials.gov/ct2/show/NCT00473525
^ https://www.rcsb.org/structure/3F8S
^ Sharma R, Sun H, Piotrowski DW, Ryder TF, Doran SD, Dai H, Prakash C (2012 yil noyabr). "((3,3-Difluoropyrrolidin-1-yl) ((2 S, 4 S) -4- (4- (pirimidin-2-yl) piperazin-1-yl) pirrolidin-2" ning metabolizmi, chiqarilishi va farmakokinetikasi. -yl) metanon, Dipeptidil Peptidaza inhibitori, kalamush, it va odamda ". Giyohvand moddalar almashinuvi va joylashishi. 40 (11): 2143–2161. doi:10.1124 / dmd.112.047316. ISSN 0090-9556. PMID 22896728. S2CID 14277073.
^ Lafrance D, Caron S (2012 yil yanvar). "Dipeptidil peptidaza-4 inhibitori uchun yangi sintetik yo'l". Organik jarayonlarni o'rganish va rivojlantirish. 16 (3): 409–14. doi:10.1021 / op200309z.
^ Nedosugova LV, Petunina NA, Galstyan KO (2014). "Rossiyada 2-toifa diabet uchun yangi dipeptidil peptidaza-4 inhibitori gosogliptinning samaradorligi va xavfsizligini dastlabki tekshirish". Qandli diabet. 17 (4): 81–86. doi:10.14341 / DM2014481-86.
^ Galstyan KO, Nedosugova LV, Petunina NA, Traxtenberg JA, Vostokova NV, Karavaeva OV, Chasovskaya TE (2016 yil aprel). "Rossiyaning DPP-4 inhibitori gosogliptinni 2-toifa diabet mellitusli bemorlarda vildagliptin bilan taqqoslash". Qandli diabet. 19 (1): 89‐96. doi:10.14341 / DM7233.
^ https://clinicaltrials.gov/ct2/show/NCT03088670
^ "SatRx MChJ Rossiyada SatRx (gosogliptin), 2-toifa diabetni davolash uchun innovatsion dori-darmonlarni birinchi ro'yxatdan o'tkazilishini e'lon qiladi" (Matbuot xabari). SatRx MChJ.

Bu dori ga tegishli maqola oshqozon-ichak tizimi a naycha. Siz Vikipediyaga yordam berishingiz mumkin uni kengaytirish.

[1] Ammirati MJ, Andrews KM, Boyer DD, Brodeur AM, Danley DE, Doran SD, Hulin B, Liu S, McPherson RK, Orena SJ, Parker JC, Polivkova J, Qiu X, Soglia CB, Treadway JL, VanVolkenburg MA, Wilder DC , Piotrowski DW (2009 yil aprel). "(3,3-Difloro-pirrolidin-1-il) - [(2S, 4S) - (4- (4-pirimidin-2-yl-piperazin-1-yl) -pirrolidin-2-yl] -metanon: kuchli, selektiv, og'iz orqali faol dipeptidil peptidaza IV inhibitori ". Bioorganik va tibbiy kimyo xatlari. 19 (7): 1991–1995. doi:10.1016 / j.bmcl.2009.02.041. PMID 19275964.

[2] Dai H, Gustavson SM, Preston GM, Eskra JD, Calle R, Hirshberg B (2008). "Sog'lom kattalar sub'ektlarida DPP-IV inhibisyonuna javoban GLP-1 darajasining chiziqli bo'lmagan o'sishi". Qandli diabet, semirish va metabolizm. 10 (6): 506–513. doi:10.1111 / j.1463-1326.2007.00742.x. PMID 18284437. S2CID 13417601.

[3] Dai H, Jonson SL, Terra SG, Marbury TC, Smit VB, Alkorn H, Boyd RA, Vang R, Nguyen TT (iyul 2011). "Buyrak etishmovchiligida bo'lgan DPP-IV inhibitori PF-734200 farmakokinetikasi". Britaniya klinik farmakologiya jurnali. 72 (1): 85–91. doi:10.1111 / j.1365-2125.2011.03954.x. PMC 3141189. PMID 21366665.

[4] Muto C, Dai H, Teeter JG, Jonson S, Cropp AB, Chiba K, Suwa T (2012). "Sog'lom yapon sub'ektlarida DPP-IV inhibitori PF-00734200 ning farmakokinetikasi va farmakodinamikasi". Xalqaro klinik farmakologiya va terapiya jurnali. 50 (7): 505–509. doi:10.5414 / CP201614. PMID 22541754.

[5] Rosenstock J, Lewin AJ, Norwood P, Somayaji V, Nguyen TT, Teeter JG, Jonson SL, Dai H, Terra SG (2011). "2-toifa diabetda metforminga qo'shilgan dipeptidil peptidaza-4 inhibitori PF ‐ 734200 ning samaradorligi va xavfsizligi". Diabetik tibbiyot. 28 (4): 464–469. doi:10.1111 / j.1464-5491.2010.03181.x. PMID 21392067. S2CID 205550845.

[6] ttps://clinicaltrials.gov/ct2/show/NCT00618007

[7] ttps://clinicaltrials.gov/ct2/show/NCT00473525

[8] ttps://www.rcsb.org/structure/3F8S

[9] Sharma R, Sun H, Piotrowski DW, Ryder TF, Doran SD, Dai H, Prakash C (2012 yil noyabr). "((3,3-Difluoropyrrolidin-1-yl) ((2 S, 4 S) -4- (4- (pirimidin-2-yl) piperazin-1-yl) pirrolidin-2" ning metabolizmi, chiqarilishi va farmakokinetikasi. -yl) metanon, Dipeptidil Peptidaza inhibitori, kalamush, it va odamda ". Giyohvand moddalar almashinuvi va joylashishi. 40 (11): 2143–2161. doi:10.1124 / dmd.112.047316. ISSN 0090-9556. PMID 22896728. S2CID 14277073.

[10] Lafrance D, Caron S (2012 yil yanvar). "Dipeptidil peptidaza-4 inhibitori uchun yangi sintetik yo'l". Organik jarayonlarni o'rganish va rivojlantirish. 16 (3): 409–14. doi:10.1021 / op200309z.

[11] Nedosugova LV, Petunina NA, Galstyan KO (2014). "Rossiyada 2-toifa diabet uchun yangi dipeptidil peptidaza-4 inhibitori gosogliptinning samaradorligi va xavfsizligini dastlabki tekshirish". Qandli diabet. 17 (4): 81–86. doi:10.14341 / DM2014481-86.

[12] Galstyan KO, Nedosugova LV, Petunina NA, Traxtenberg JA, Vostokova NV, Karavaeva OV, Chasovskaya TE (2016 yil aprel). "Rossiyaning DPP-4 inhibitori gosogliptinni 2-toifa diabet mellitusli bemorlarda vildagliptin bilan taqqoslash". Qandli diabet. 19 (1): 89‐96. doi:10.14341 / DM7233.

[13] ttps://clinicaltrials.gov/ct2/show/NCT03088670

[14] "SatRx MChJ Rossiyada SatRx (gosogliptin), 2-toifa diabetni davolash uchun innovatsion dori-darmonlarni birinchi ro'yxatdan o'tkazilishini e'lon qiladi" (Matbuot xabari). SatRx MChJ.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]

[12]

[13]

[14]

Navigation

Navigation

Themenportale

WikiDer > Gosogliptin

Adabiyotlar